Select a company

Go

Company Stage

  • Private (seed)
  • Private (post-seed)
  • Quoted

Sector

  • Biotech
  • Healthcare
  • Cleantech
  • Technology
  • Other

University

  • University of Bath
  • University of Bristol
  • University of Cardiff
  • University of Glasgow
  • University of Leeds
  • King's College London
  • Queen Mary, University of London
  • University of Manchester
  • University of Nottingham
  • University of Oxford
  • University of Sheffield
  • University of Southampton
  • University of Surrey
  • Swansea University
  • University of York
  • Other

Stakeholder

  • IP Group
  • IP Venture Fund
  • IP Venture Fund II
  • Top 10 Holdings
    by value
Pharma & Biotech

University: Southampton

Company Stage: Quoted

Website: http://www.synairgen.com

Synairgen's objective is the discovery and development of novel treatments for chronic respiratory disorders including asthma. Led by the world renowned Professor Stephen Holgate, the founding scientists have pioneered research into the underlying causes of respiratory diseases.

In particular, Synairgen has demonstrated that genetic make-up is critical to both the development and progression of these conditions. In doing so, potential new therapeutic targets have been identified.

As at 31 Dec 2013

IP Group holding

IP Venture Fund* holding

10.8%

7.4%

*IP Group has a 10%
economic interest in IP
Venture Fund

Holdings represent undiluted beneficial equity interest excluding debt